LENSAR (LNSR) Expected to Release Earnings on Thursday

LENSAR (NASDAQ:LNSR) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect LENSAR to announce earnings of ($0.1650) per share and revenue of $14.65 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

LENSAR (NASDAQ:LNSR) last posted its quarterly earnings data on Friday, May 8th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $1.38. The business had revenue of $13.43 million during the quarter, compared to analyst estimates of $13.40 million. LENSAR had a negative return on equity of 183.19% and a net margin of 50.94%.

LENSAR Price Performance

Shares of LENSAR stock traded up $0.18 on Tuesday, reaching $5.56. The company had a trading volume of 7,655 shares, compared to its average volume of 83,693. The firm has a market cap of $68.28 million, a price-to-earnings ratio of -9.59 and a beta of 0.89. The firm’s 50-day moving average price is $5.78 and its two-hundred day moving average price is $7.70. LENSAR has a 1 year low of $4.95 and a 1 year high of $13.20.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings upgraded shares of LENSAR from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of LENSAR from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, LENSAR presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Trading of LENSAR

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in LENSAR by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock worth $6,269,000 after buying an additional 1,446 shares during the period. Geode Capital Management LLC grew its stake in LENSAR by 103.9% in the 2nd quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock worth $2,890,000 after acquiring an additional 111,802 shares in the last quarter. State Street Corp grew its stake in LENSAR by 4.6% in the 4th quarter. State Street Corp now owns 123,720 shares of the company’s stock worth $1,439,000 after acquiring an additional 5,470 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of LENSAR by 42.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 89,003 shares of the company’s stock worth $1,035,000 after acquiring an additional 26,715 shares during the period. Finally, Gabelli Funds LLC increased its position in shares of LENSAR by 11.8% during the third quarter. Gabelli Funds LLC now owns 57,000 shares of the company’s stock worth $704,000 after acquiring an additional 6,000 shares during the period. 40.15% of the stock is owned by hedge funds and other institutional investors.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.